HighTower Advisors LLC trimmed its position in Medtronic PLC (NYSE:MDT – Free Report) by 5.3% during the third quarter, HoldingsChannel.com reports. The fund owned 372,348 shares of the medical technology company’s stock after selling 20,980 shares during the period. HighTower Advisors LLC’s holdings in Medtronic were worth $32,130,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Gradient Investments LLC increased its position in Medtronic by 3.9% during the 2nd quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after purchasing an additional 18,509 shares during the period. Congress Asset Management Co. acquired a new stake in shares of Medtronic in the 3rd quarter valued at approximately $76,201,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Medtronic by 14.8% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 149,708 shares of the medical technology company’s stock valued at $12,918,000 after buying an additional 19,315 shares during the period. Worth Asset Management LLC purchased a new stake in shares of Medtronic in the third quarter valued at approximately $1,056,000. Finally, Czech National Bank boosted its stake in shares of Medtronic by 4.7% in the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock valued at $28,589,000 after buying an additional 16,292 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.
Wall Street Analyst Weigh In
MDT has been the topic of a number of recent analyst reports. Deutsche Bank reaffirmed a “hold” rating and set a $92.00 price objective on shares of Medtronic in a report on Thursday, September 3rd. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Mizuho set a $115.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Robert W. Baird upped their price target on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 2nd. Finally, Stifel Nicolaus increased their price target on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.17.
View Our Latest Stock Report on MDT
Insiders Place Their Bets
In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Marinaro sold 10,420 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is owned by corporate insiders.
Medtronic Price Performance
Shares of NYSE:MDT opened at $99.88 on Friday. The business’s 50 day simple moving average is $94.62 and its 200-day simple moving average is $88.45. The firm has a market capitalization of $127.75 billion, a price-to-earnings ratio of 24.60, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period last year, the business posted $1.26 EPS. Medtronic’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.
Medtronic Company Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
See Also
- Five stocks we like better than Medtronic
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
